Therapeutic areas: Neurology
Post-Aduhelm controversy, Biogen reps are navigating a portfolio reset anchored by Leqembi (lecanemab) for early Alzheimer\
Key products: Leqembi, Tysabri, Plegridy, Skyclarys, Spinraza
Post-Aduhelm controversy, Biogen reps are navigating a portfolio reset anchored by Leqembi (lecanemab) for early Alzheimer\